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Abstract
Background: Cluster headache (CH) is a debilitating headache disorder with severe consequences for patient
quality of life. On-demand neuromodulation targeting the sphenopalatine ganglion (SPG) is effective in treating the
acute pain and a subgroup of patients experience a decreased frequency of CH attacks.
Methods: We monitored self-reported attack frequency, headache disability, and medication intake in 33 patients
with medically refractory, chronic CH (CCH) in an open label follow-up study of the original Pathway CH-1 study.
Patients were followed for at least 24 months (average 750 ± 34 days, range 699-847) after insertion of an SPG
microstimulator. Remission periods (attack-free periods exceeding one month, per the ICHD 3 (beta) definition)
occurring during the 24-month study period were characterized. Attack frequency, acute effectiveness, medication
usage, and questionnaire data were collected at regular clinic visits. The time point “after remission” was defined as
the first visit after the end of the remission period.
Results: Thirty percent (10/33) of enrolled patients experienced at least one period of complete attack remission. All
remission periods followed the start of SPG stimulation, with the first period beginning 134 ± 86 (range 21-272) days after
initiation of stimulation. On average, each patient’s longest remission period lasted 149 ± 97 (range 62-322) days. The
ability to treat acute attacks before and after remission was similar (37 % ± 25 % before, 49 % ± 32 % after; p = 0.2188).
Post-remission headache disability (HIT-6) was significantly improved versus baseline (67.7 ± 6.0 before, 55.2 ± 11.4 after;
p = 0.0118). Six of the 10 remission patients experienced clinical improvements in their preventive medication use. At
24 months post insertion headache disability improvements remained and patient satisfaction measures were positive in
100 % (10/10).
Conclusions: In this population of 33 refractory CCH patients, in addition to providing the ability to treat acute attacks,
neuromodulation of the SPG induced periods of remission from cluster attacks in a subset of these. Some patients
experiencing remission were also able to reduce or stop their preventive medication and remissions were accompanied
by an improvement in headache disability.
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Background
Cluster headache (CH) is considered the most painful
primary headache disorder. In the episodic form (ECH)
bouts of attacks alternate with periods of remission of
varying duration. In the chronic form such remissions
are lacking or shorter than 1 month through at least
1 year [1]. Because of the multiple daily attacks, social
and economic consequences for patients are severe.
CCH impairs daily functioning and reduces quality of
life: 75 % of patients report severe disability, 20 % have
suicidal tendencies, and 20 % are unemployed or receive
government disability compensation [2–4]. A study of
179 patients in Germany concluded that mean annual
direct and indirect costs were significant [5].
Standard treatment includes verapamil and/or lithium
as prophylactic therapy and oxygen or triptans (inject-
able or nasal) for acute attacks [6]. Still, many CH pa-
tients are undertreated due to insufficient management
or risk factors and side effects associated with estab-
lished treatment options. Moreover, a subset of CH pa-
tients are refractory or have only limited benefit from
standard medical treatments (see [7] for definition of re-
fractory CH). New, promising treatment options have
become available that may provide relief to these insuffi-
ciently treated patients. Among them, neuromodulation
has become a viable clinical option thanks to techno-
logical advances.
The prominent autonomic features and the pain
during CH attacks are attributed to activation of a
trigemino-autonomic reflex that is mediated through
the sphenopalatine ganglion (SPG) (also called the
pterygopalatine ganglion). The SPG connects directly
and indirectly with the hypothalamus, superior salivatory
nucleus (SSN), trigemino-vascular system, meninges, and
somatic and autonomic nerves innervating cranial struc-
tures and is thus a crucial part of the trigemino-
parasympathetic circuit and a well-recognized target of
therapeutic intervention, including neuromodulation [8, 9].
Various direct manipulations of the SPG including steroid/
alcohol injections, radiofrequency ablation, surgical resec-
tion, and gamma knife surgery act as proofs of concept but
are not viable clinical options, as therapeutic effects may
be short-lasting, requiring repeated procedures, or side-
effects are poorly tolerated.
The development of an implantable microstimulator
affixed to the maxilla, with electrodes placed in the pter-
ygopalatine fossa proximate to the SPG, allows for re-
versible, repeated, targeted stimulation of the SPG, and
its short- and long-term acute effects and safety have
already been documented [10–12]. SPG stimulation,
with the correct stimulation paradigm, likely interrupts
the trigemino-autonomic reflex inhibiting efferent out-
flow, i.e. the final common pathway for parasympathetic
activation in CH [13, 14].
Although not an endpoint of the original, randomized,
controlled Pathway CH-1 study, the investigators became
aware of an unexpected preventive effect, in addition to
the already reported acute effect of SPG stimulation [11].
After stimulation was initiated, a subset of patients began
to notice reductions in cluster attack frequency and had
attack-free periods, lasting weeks or months. We aimed to
characterize these remission periods in more detail over a
follow-up period of 24 months.
Methods
In the original Pathway CH-1 study, CCH patients
underwent trans-oral insertion of a microstimulator,
such that the stimulating electrodes were placed suffi-
ciently proximate to the SPG to allow for targeted neu-
rostimulation of this structure. Additional insertion
details have previously been published [15, 16]. Patients
were followed for 12 months following microstimulator
insertion. During this time, efficacy of SPG stimulation
was initially evaluated in a randomized, controlled, ex-
perimental period [11]. Following this phase and during
the first 12 months post insertion, patients had the op-
portunity to use the therapy in an open label period.
After the first 12 months an extended long term follow-
up study (LTFU) was initiated so that follow-up beyond
the original study was possible. Visits during the first
12 months post-insertion occurred at intervals ranging
from every two weeks to every three months, and during
the second year, every three months. Data from micro-
stimulator insertion through 24 months post-insertion
were analysed, and results are presented for patients en-
rolled in the extended follow-up study who experienced
remission from attacks.
Patient selection
Inclusion and exclusion criteria for the original Pathway
CH-1 study and the LTFU have been published previ-
ously [11, 12]. Briefly, participants were medically refrac-
tory CCH patients with a minimum of four attacks/week
[17, 18]. Enrolment in the LTFU required participation
in the Pathway CH-1 study, continued microstimulator
implantation, compliance with study protocol, and writ-
ten informed consent. Reasons for not being enrolled in
the LTFU included unwillingness to follow the protocol
or lack of signed informed consent. Both studies were
approved by the appropriate competent national,
regional, and/or institutional review boards at all
participating centers. Studies were registered on
clinicaltrials.gov (NCT01255813 and NCT01616511).
Data collection
Acute response to SPG stimulation was captured pro-
spectively in an electronic headache diary incorporated
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into the remote controller. Pain scores are reported using
the Categorical Pain Scale (CPS) [0-none, 1-mild, 2-
moderate, 3-severe, 4-very severe]. Headache pain was
reported prior to stimulation use, upon turning on the
remote control, and again along with acute medication
use at either 15 min following the start of stimulation (0-
12 months post-insertion), or immediately following ces-
sation of each SPG stimulation session (12-24 months
post-insertion). Attack frequency (recollection or diary
over past four weeks), preventive medications, and head-
ache disability (HIT-6 headache impact test) [19] were
captured prior to implant and at each study visit referring
to the previous 4 weeks. With regards to the study visits
and duration, 28 days was considered to be one month.
Outcomes and analyses
During the second year of the study, clinic visits oc-
curred every 3 months, and patients were asked to rec-
ord their average cluster attack frequency over the prior
4 weeks. Attack frequency data were imputed using data
from the subsequent clinic visit. Post-hoc analyses evalu-
ating attack frequency over the entire 24 month study
period were performed. Per the ICHD-3 (beta) criteria, a
cluster remission period is defined as “the time during
which attacks cease to occur spontaneously and cannot
be induced with alcohol or nitroglycerine. To be consid-
ered a remission the attack-free period must exceed one
month”[1]. In the analysis herein, remission patients ex-
perienced zero cluster attacks for longer than one month
following active use of SPG stimulation, as reported on
the case report form. Induction of attacks using alcohol
or nitroglycerine was not attempted.
Acute effectiveness is defined as pain relief (decrease
in CPS score from 2 (moderate) or greater to 1 (mild) or
0 (none) without the use of acute medications) or pain
freedom (CPS score decreased from 1 (mild) or greater
to 0 (none) without the use of acute medications)
following SPG stimulation of an acute attack. Acute ef-
fectiveness was evaluated in all patients with remission
for all evaluable SPG stimulation attempts (i.e., those
with completed electronic headache diary data; sham
and sub-perception attempts during the randomized,
controlled experimental period were excluded). Acute
effectiveness pre- and post-remission was compared
using the Wilcoxon signed rank test. In patients experi-
encing more than one remission period, the longest
remission period was used.
Use of preventive medications, headache disability,
and patient experiences with SPG stimulation were eval-
uated at the study visit following the longest remission
period at which these data were collected. Within-
patient, headache disability improvements were consid-
ered clinically significant if scores improved by at least
2.5 units relative to baseline [19]. Differences in baseline
characteristics between patients with remission and
those without were calculated using t-test (age, years of
CH, HIT-6), Fisher’s exact test (gender), and Wilcoxon
rank sum test (attack frequency).
SPG Microstimulator system
The SPG Microstimulator (also referred to as the ATI
Neurostimulator and the PulsanteTM SPG Microstimula-
tor) is designed to fit the facial anatomy with an inte-
grated lead placed proximate to the SPG. The
microstimulator communicates with a handheld remote
controller using radiofrequency, is inductively powered,
and contains no battery [11]. Using the remote control-
ler, patients apply on-demand SPG stimulation to treat
the acute pain of their cluster attacks. Later in the study,
some patients started stimulating prophylactically, i.e. in
a painless state, without treating acute attacks, as a re-
sult of the unanticipated finding of a preventative effect
of SPG stimulation. As this was unexpected, no data was
systematically collected regarding prophylactic stimula-
tion. Electronic diaries indicate that some patients used
prophylactic stimulation extensively, others sparsely.
Results
Thirty-three medically refractory CCH patients partici-
pated in the extended follow-up through 24 months
post-insertion (Table 1). Average time from microstimu-
lator insertion through 24 months post-insertion was
750 ± 34 days, (range 699-847). Average duration of CH
at baseline was 10.5 ± 8.3 years (range 1-36), with an
Table 1 Clinical baseline characteristics (mean ± SD) from the total population and sub-populations of patients with and without
remission are presented
Clinical baseline characteristics Total
(N = 33)
CCH with no remission
(N = 23)
CCH with remission
(N = 10)
P-values
(with and without remission)
Age 41.5 ± 12.0 40.7 ± 12.7 43.3 ± 10.7 p = 0.5698
Male/female 5.6:1 6.6:1 4:1 p = 0.6269
Attacks/week at baseline
(recalled over 4 weeks)
16.8 ± 13.7 16.6 ± 14.1 17.3 ± 13.3 p = 0.9689
Years of CH at baseline 10.5 ± 8.3 11.0 ± 9.6 9.6 ± 4.6 p = 0.5851
HIT-6 score at baseline 66.7 ± 6.2 66.2 ± 6.4 67.7 ± 6.0 p = 0.5366
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average attack frequency of 16.8 ± 13.7 attacks/week
(range 5-70).
Ten patients (30 %) experienced one or more remission
periods lasting at least one month (Fig. 1). One additional
patient experienced a continuous period of 28 days without
attacks following initiation of stimulation, but was not in-
cluded in the analysis. The initial attack free period oc-
curred after the start of SPG stimulation in all 10 patients:
159 ± 91 days, range 42-306, following microstimulator in-
sertion and 134 ± 86 days, range 21-272, following start of
stimulation. For these 10 patients, at the clinic visit when
stimulation was first started, average attack frequency was
16.4 ± 16.8 attacks/week (range 3.5-60, compared with
baseline (all 33 patients) p = 0.7090). Each patient’s longest
attack-free period lasted 149 ± 97 days (range 62-322).
The number of distinct remission periods varied between
patients, with four patients experiencing only one, five pa-
tients experiencing two, and one patient experiencing
three distinct remission periods. During the remission pe-
riods, patients used SPG stimulation as in a painless state
(i.e. as prevention), on average, 1.3 ± 1.5 (range 0-4.3)
times per week although no specific instructions regarding
stimulator use outside of attacks were provided by investi-
gators. Before and after the longest remission period, this
patient population (N = 10) treated 374 and 217 evaluable
attacks, respectively. Average acute effectiveness per pa-
tient was unchanged pre- and post-remission (p = 0.2188)
(Table 2).
Improvements in headache impairment and acute and
preventive medications post-remission
Post-remission headache impairment and medication
data collection coincided with the visit at which the
longest remission period ended for 7 patients, occurred
at a clinic visit following the longest remission in 2 pa-
tients, and occurred at a clinic visit after the start of, but
prior to the ending of the longest remission period in 1
patient. The 10 patients experiencing cluster attack remis-
sion were all severely disabled by their headaches prior to
entering the Pathway CH-1 study, scoring 67.7 ± 6.0
(range 58-76) on the HIT-6. Following the remission,
scores improved to 55.2 ± 11.4 (range 40-73) (Fig. 2). The
improvement was more than eight times the between-
group minimally important difference of -1.5 [19] and was
statistically significant (p = 0.0118). Patients experiencing
remission during the first 24 months of microstimulator
use continued to see improvements in headache impair-
ment; 70 % (7/10) were HIT-6 responders, experiencing a
clinically meaningful improvement in headache disability.
Impairment scores in patients experiencing remission
(67.7 ± 6.0 at baseline improved to 60.0 ± 8.5 at 24 months)
were not different from non-remission patients’
(66.2 ± 6.4 at baseline improved to 62.4 ± 9.7 at
24 months) (p = 0.1997).
All ten patients who experienced remission used trip-
tans at baseline. At 24 months post-insertion, 6/10 used
no triptans, with 3/10 using no acute treatments at all
(Table 3). Clinical improvements in preventive CH medi-
cation use (reduction in dose, stopping medications, or
remaining off medications) were observed in 4/10
patients post-remission, and 6/10 patients at 24 months
post-insertion (Table 3). There were no obvious patterns
in dose changes before or during remission periods.
All 10 remission patients also completed a questionnaire
evaluating their experience with SPG stimulation at
24 months. All indicated that SPG stimulation was useful
for treating their headaches, and they would recommend
SPG stimulation to someone else suffering from CH. All
Fig. 1 Remission Periods per patient. periods of complete attack remission for the 10 patients experiencing remission. Data through the entire study
period, from microstimulator insertion to the 24 month study visit are provided. X’s indicate first use of stimulator. Squares indicate 24 month study visit
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10 also indicated they would make the same decision
again to use SPG stimulation to treat their attacks, and
that they found the inserted microstimulator comfortable
and the sensation of stimulation tolerable.
Discussion
In addition to the acute and preventive effects previously
reported [11, 12], long-term SPG stimulation induced a
state of headache remission of varying duration in 30 %
of patients considered drug refractory. According to
current diagnostic criteria (ICHD-3 beta), remission pe-
riods, as described above, effectively mean that the
patient’s diagnostic status changes from chronic to epi-
sodic within one year. The clinical significance of this
change was substantiated by an improvement in
headache disability and a considerable reduction in use
of acute and preventive medications.
Even though understanding of the trigeminal auto-
nomic reflex and the involved central mechanisms has
improved over the past years [14], a discussion of the
possible mechanisms behind the effects observed in this
study remains hypothetical. CH is the headache disorder
with the strongest chronobiological traits, and it is char-
acterized by a non-static level of activity [20]. The epi-
sodic variant has distinct periods of attacks and
remissions, however, even in the state of remission,
pathological processes may still be present. Likewise,
despite the designation of chronic, CCH patients also ex-
perience fluctuations in attack frequency [20]. Therefore,
the absence of manifest headache may not signal ab-
sence of pathology. In this regard, it is particularly inter-
esting whether continued use of SPG stimulation may
prolong the period of remission, or indeed, in non-
remission patients, whether SPG stimulation in the
attack-free state may prevent future attacks. Whether
application of SPG stimulation in a preventive fashion
during the remission period actually prolonged the re-
mission period is unknown, and remains a theoretical
discussion as data at present do not allow for such an
analysis.
Although documentation is sparse, it is known that
both episodic and chronic CH patients either spontan-
eously, or possibly in response to treatment, transition
between phases throughout the course of their disease.
A study of 189 CH patients in Italy over 10 years reports
that approximately 20 % of ECH patients became
chronic or experienced a combination of phases, while
Table 2 Average acute effectiveness, assessed using the Wilcoxon signed rank test, is unchanged following each patient’s longest
cluster attack remission (p = 0.2188)
Acute outcomes in patients with remission
Remission
patient
Attack frequency
(attacks/wk) at
baseline
Days of stimulation
prior to first remission
Consecutive (longest)
remission duration
(days)
Calendar months
during (longest)
remission
% of attacks achieving
effective therapy
(# effective therapy/total treated)
Before Remission After Remission
1 45 212 322 Feb -> Nov 0 % (0/203) 0 % (0/1)
2 8 272 215 Dec -> Aug 62 % (18/29) 64 % (32/50)
3 7 63 182 Dec -> Jun 0 % (0/4) 46 % (6/13)
4 35 42 133 Aug -> Dec 33 % (3/9) 7 % (2/30)
5 16 238 280 Jul -> Apr 57 % (12/21) 52 % (12/23)
6 10 21 106 Jul -> Nov 38 % (11/29) 43 % (3/7)
7 20 113 64 Aug -> Oct 21 % (4/19) 56 % (14/25)
8 7 174 63 Mar -> May 47 % (14/30) 100 % (33/33)
9 5 119 63 Oct -> Dec 36 % (4/11) 33 % (1/3)
10 20 84 62 Apr -> Jun 74 % (14/19) 91 % (29/32)
Avg ± SD 17.3 ± 13.3 133.8 ± 86.3 149.0 ± 96.7 - 36.8 ± 31.8 % 49.2 ± 31.8 %
(p = 0.2188)
Fig. 2 HIT-6 Headache Disability Changes. HIT-6 scores in patients
with remission (N = 10). Improvements in HIT-6 scores from baseline
in these 10 patients are clinically (*) and statistically (#) significant at
both the post-remission and 24 month evaluation points
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47 % of CCH patients became episodic or a combination
state during the same time frame [21]. A review by the
same authors reported a rate of 14-39 % experiencing
prolonged remission periods [22]. To underline the cyc-
lic nature of the disorder, in a recent paper we found in
fact that some patients also increase in frequency [12].
The possibility therefore exists that the observed periods
of remission in this study were entirely spontaneous;
however, given the different patient populations with
drug refractory patients in our cohort, it seems it seems
likely that the observed remission periods were induced
by SPGS. Another possibility is that the remission pe-
riods were induced by the surgery associated with inser-
tion of the microstimulator. However, the lag between
surgery and remission, as well as the continued acute ef-
fectiveness of stimulation after the remission periods
would seem to preclude this surgical effect. Additionally,
no obvious pattern regarding the months during which
remissions occurred can be found, suggesting that there
was no relevant chronobiological influence. Therefore, it
is likely that the remission periods were in fact induced
by SPG neuromodulation. Considering that many of the
observed remission periods were quite long, one might
expect a larger percentage of patients to have reduced
or stopped preventive medication. However, CH
patients are often quite reluctant to reduce preventive
medication during remission periods in fear of trigger-
ing a new cluster. This tendency may explain the
reduction in preventive medications in only ~1/3 of
the remission patients.
While a mechanism of action remains unknown, sev-
eral hypotheses for how SPG stimulation may induce a
preventive effect could be proposed. SPG stimulation
may cause activation of sensory fibers from the second
division of the trigeminal nerve (V2). V2 axons traverse
the SPG and converge on second-order neurons in the
trigeminal nucleus caudalis (TNC) together with V1 af-
ferents. Alternatively, antidromic input to the SSN may
produce changes in brainstem and hypothalamic circuits
involved in CH attacks [23].
Major unresolved issues remain nosologic. Can a CCH
patient using ongoing SPG stimulation who has been
pain-free for at least one month be reclassified as ECH?
Must the patient have at least two cluster periods sepa-
rated by at least one month of no attacks to be classified
as ECH? When CCH patients are treated with SPG
stimulation or daily drug-based preventive therapy and
have no attacks while receiving treatment, should the
diagnosis be changed to ECH? How long must a CH pa-
tient be without any attacks before being re-classified as
in complete remission? Of note, the term complete CH
remission is not covered by the ICHD-3 (beta) which
likely needs to be defined and adopted.
Our analysis has several limitations, primarily stem-
ming from the fact that the preventive effect was unex-
pected at the time of the original protocol design which
Table 3 Post-remission indicates the first visit after the remission period ended where attack frequency, medication, and questionnaire
data were collected; In two patients (patients 1 and 10), the visit at which medication data were collected (i.e., post-remission visit)
occurred after remission had started, and the remission period had not yet ended at that time
Acute and preventive medication use in patients with remission
Remission
patient
Acute CH medications Preventive CH medications
Baseline Post-remission 24 Month Baseline Post-remission 24 Month
1 Zolmitriptan Oxygen* Oxygen* Valproic acid None* None*
2 Sumatriptan,
oxygen
None* Sumatriptan,
oxygen
Verapamil Verapamil Verapamil, gabapentin
3 Sumatriptan Sumatriptan Sumatriptan Verapamil, lithium Verapamil, lithium None*
4 Sumatriptan None* None* Topiramate None* None*
5 Sumatriptan None* None* Verapamil, lithium,
gabapentin
Gabapentin Gabapentin*
6 Zolmitriptan,
oxygen
Frovatriptan Oxygen* Verapamil, lithium None* Verapamil
7 Sumatriptan,
oxygen
None* Sumatriptan Verapamil, lithium,
gabapentin
Verapamil, lithium,
gabapentin
Verapamil, gabapentin,
lithium
8 Sumatriptan,
oxygen
None* None* Candesartan Candesartan Candesartan
9 Sumatriptan n.a. Sumatriptan None n.a. None*
10 Sumatriptan,
oxygen
None* Oxygen* Verapamil None* None*
Data on post-remission acute and preventive CH medications are not available in patient 9 (n.a.). *Patients who stopped acute triptan use or had a clinical improvement
in or remained off all preventive meds
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only evaluated acute effectiveness in a controlled man-
ner where each patient served as their own control. To
this end, only a brief baseline period of four weeks was
required, however, this rather short baseline proved to
be a limitation with regards to evaluating the remission
periods, as it cannot be ruled out completely that the
observed remissions are spontaneous. Individual patient
histories concerning the change in subtype (ECH, CCH)
were not systematically collected at baseline. However,
as all patients enrolled had been diagnosed with CCH
without periods of remission for at least one year, it is
unlikely that these periods of remission were purely due
to natural fluctuations in attack frequency. Furthermore,
during the second year of the study, data were collected
every three months retrospectively for the preceding
month. Therefore, attack frequency data were imputed
to fill the gaps of two months and were thus also subject
to recall bias in patients not using a diary. Since by def-
inition this study evaluated periods of remission lasting
greater than one month, we believe the impact of this
imputation to be negligible.
As the remission periods were unanticipated, provoca-
tion of attacks with alcohol or nitroglycerine was not
attempted. Further, instruction on and use of SPG
stimulation outside of attacks was not consistent. Thus,
it is difficult to draw conclusions regarding the impact of
preventive stimulation, or even the implantation proced-
ure itself and further studies in this regard are war-
ranted. Although patients were asked to treat each
attack with SPG stimulation, we cannot rule out that
few attacks were not recorded in the electronic diary in
patients who chose not to treat attacks.
Finally, it is worth contrasting the effectiveness results
from this 24 month follow-up open-label study with
those open-label extension trials required by the US and
other competent authorities for establishing safety of
preventive medications. In the typical pharmacologic
open label extension trials, only the responders usually
remain on the medication for the duration of the study,
while non-responders drop out. This selection bias is
one of the reasons why open label extension trials are
not used for efficacy evaluations. However, with an im-
planted device, all of the patients agreeing to participate
were followed for 24 months, allowing for evaluation of
efficacy in the entire group. The entire implanted group
remained intact for the study period, thus effectiveness
is a reasonable outcome assessment. Therefore, detailed
trial guidelines for study design and outcome parameters
in the area of neuromodulation should be developed.
Conclusions
SPG stimulation provides not only acute effectiveness
but also reduces attack frequency. In reducing the fre-
quency, some patients experience complete attack
remission, effectively converting to the episodic CH sub-
type. SPG stimulation’s ability to acutely treat CH at-
tacks is maintained, providing acute relief both before
and after remission. Following the remission, headache
disability is reduced, and some patients can also reduce
their use of medications. Long term investigations into
remission periods and possible pathophysiological
mechanisms are warranted, as is consideration for re-
definitions of episodic CH and complete remission.
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